Objective: New disease-modifying treatment strategies in multiple sclerosis offer possibilities
for individualised treatment. In this study, we evaluated patient-reported outcome measures …

Objective: To compare treatment effectiveness and persistence in relapsing-remitting
multiple sclerosis patients who initiated rituximab versus glatiramer acetate (GA) or …

Background Rituximab (RTX) is an extensively used off-label drug for multiple sclerosis
(MS), whereas the induction and maintenance regimens vary widely among studies. Few …

Objective: To investigate the efficacy of rituximab as rescue therapy in patients with
relapsing-remitting multiple sclerosis (RRMS) and persistent disease activity confirmed by …

Background Rituximab is safe and effective for treating relapsing–remitting multiple sclerosis
(RRMS) according to phase II and observational studies. There are limited data on disease …

Background Rituximab (RTX) and other anti-CD20 therapies are increasingly used as
disease modifying treatments (DMTs) in MS. However, data on reasons to interrupt …

Background Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS).
More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo …

Objective: To describe the effects of switching treatment from ongoing first-line injectable
therapies to rituximab on inflammatory activity measured by MRI and levels of CSF …

Objective. To evaluate the efficacy and safety of rituximab in multiple sclerosis in a clinical
practice setting. Methods. Clinical data for all adult patients with multiple sclerosis (MS) …

Importance Comparative real-world effectiveness studies of initial disease-modifying
treatment (DMT) choices for relapsing-remitting multiple sclerosis (RRMS) that include …